These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1505 related articles for article (PubMed ID: 17485023)

  • 1. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
    Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
    Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
    Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.
    Fogari R; Derosa G; Zoppi A; Preti P; Lazzari P; Destro M; Fogari E; Rinaldi A; Mugellini A
    Am J Hypertens; 2007 Apr; 20(4):417-22. PubMed ID: 17386350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
    Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J
    Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
    Bahadir O; Uzunlulu M; Oguz A; Bahadir MA
    Hypertens Res; 2007 Jan; 30(1):49-53. PubMed ID: 17460371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
    Murakami K; Wada J; Ogawa D; Horiguchi CS; Miyoshi T; Sasaki M; Uchida HA; Nakamura Y; Makino H
    Diab Vasc Dis Res; 2013 Jan; 10(1):93-6. PubMed ID: 22561230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
    Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
    Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets).
    Shishido T; Konta T; Nishiyama S; Miyashita T; Miyamoto T; Takasaki S; Nitobe J; Watanabe T; Takeishi Y; Kubota I
    Clin Exp Hypertens; 2011; 33(2):117-23. PubMed ID: 21269062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus.
    Kulkarni RB; Kulkarni BN; Hariharan RS; Naikwadi A; Gawde A; Baliga V; Desai A
    J Indian Med Assoc; 2005 Mar; 103(3):187-91. PubMed ID: 16173297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
    Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
    Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
    Mori Y; Tanaka T; Matsuura K; Yokoyama J; Utsunomiya K
    Adv Ther; 2011 Aug; 28(8):698-706. PubMed ID: 21744143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
    Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R
    Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
    Kishi T; Hirooka Y; Konno S; Sunagawa K
    J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
    Shimabukuro M; Tanaka H; Shimabukuro T
    J Hypertens; 2007 Apr; 25(4):841-8. PubMed ID: 17351377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
    Makino H; Haneda M; Babazono T; Moriya T; Ito S; Iwamoto Y; Kawamori R; Takeuchi M; Katayama S;
    Hypertens Res; 2008 Apr; 31(4):657-64. PubMed ID: 18633177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.